About Idenix Pharmaceuticals
Idenix Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix is headquartered in Cambridge, Massachusetts (USA). The Company's clinical development operations and drug discovery operations are conducted in Cambridge and in the Company's European laboratories in Montpellier, France. Idenix's current focus is on the treatment of patients with hepatitis C infection.
Idenix Pharmaceuticals Patents
Idenix Pharmaceuticals has filed 80 patents.
Molecular biology, Hepatotoxins, HIV/AIDS, Virology, Experimental drugs
Molecular biology, Hepatotoxins, HIV/AIDS, Virology, Experimental drugs
Latest Idenix Pharmaceuticals News
May 3, 2023
Published May 3, 2023 Dive Brief: Biotechnology industry veteran Ron Renaud will take over the top job at Cerevel Therapeutics after a series of delays producing clinical trial results shook investor confidence in the company. Renaud will replace Tony Coles as CEO on June 12, Cerevel said Wednesday . Coles will continue in his post as chairman of the board. In the company’s statement, Coles said he believes Renaud is ideally suited to lead Cerevel, a developer of drugs for brain diseases, in the “next phase of our journey.” Cerevel expects results from seven studies of experimental drugs in 2024, among them a closely watched schizophrenia medicine known as emraclidine. The biotech also said it has plenty of cash to support that research and fund operations into 2025. Dive Insight: Renaud comes to Cerevel with a proven track record spanning more than 25 years in the industry. While the change in top management might surprise some investors, it’s ultimately a positive move, Stifel analyst Paul Matteis wrote in a Wednesday note to clients. The company has also drawn interest for its work developing a drug to target schizophrenia in a new way. The approach has been validated by another biotech, Karuna Therapeutics, which found success in two Phase 3 studies . Cerevel’s drug, emraclidine, has also shown positive results in an early study . But Cerevel shares plummeted in late February after the company said data expected this year from trials of experimental medicines for epilepsy, Parkinson’s disease and dementia-related apathy would be delayed until 2024. While the company’s stock has largely recovered, new leadership may help reassure investors. The incoming CEO is “well known by the investor community” and has a reputation for being accessible to Wall Street, Matteis said. Renaud’s executive bona fides come from his stints as CEO of Translate Bio and Idenix Pharmaceuticals. Starting in 2007, Renaud served in roles including chief financial officer, chief business officer and CEO at Idenix, which focuses on hepatitis C medicines. Under his tenure, Idenix went from a company with a market value of $300 million to one valued at $3.85 billion in a 2014 takeover by Merck , Cerevel said. In 2014, he became chairman and CEO of a startup called RaNA Therapeutics and oversaw its transition to a public company named Translate Bio that sold to Sanofi in 2021 for $3.2 billion. Most recently, Renaud was a partner at Bain Capital Life Sciences, starting in Sept. 2022.
Idenix Pharmaceuticals Frequently Asked Questions (FAQ)
When was Idenix Pharmaceuticals founded?
Idenix Pharmaceuticals was founded in 1998.
Where is Idenix Pharmaceuticals's headquarters?
Idenix Pharmaceuticals's headquarters is located at 320 Bent Street, Cambridge.
What is Idenix Pharmaceuticals's latest funding round?
Idenix Pharmaceuticals's latest funding round is Acq - P2P.
How much did Idenix Pharmaceuticals raise?
Idenix Pharmaceuticals raised a total of $68.91M.
Who are the investors of Idenix Pharmaceuticals?
Investors of Idenix Pharmaceuticals include Merck & Co., Novartis, MPM Capital, TVM Capital, Nomura Holdings and 9 more.
Who are Idenix Pharmaceuticals's competitors?
Competitors of Idenix Pharmaceuticals include Achillion Pharmaceuticals, BioMarck Pharmaceuticals, Alios BioPharma, ViroPharma, Excaliard Pharmaceuticals, Anadys Pharmaceuticals, Affectis Pharmaceuticals, Metabasis Therapeutics, Elara Pharmaceuticals, Arpida and 17 more.
Compare Idenix Pharmaceuticals to Competitors
REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.
Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.